Scholarlink

<p>Post-transplant lymphoproliferative disorder (PTLD) is an uncommon but potentially life-threatening complication of solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). Therefore, early diagnosis and appropriate treatment are crucial. We report a case of a 37-year-old male who developed gastrointestinal-localized Epstein–Barr Virus (EBV)–associated polymorphic PTLD 5 months after kidney transplantation for diabetic nephropathy. The patient had undergone allogeneic HSCT (allo-HSCT) for acute myeloid leukemia 14 years prior and developed chronic graft-versus-host disease and secondary hypogammaglobulinemia. A reduction in immunosuppressive therapy was insufficient to control the PTLD, and the patient achieved complete remission with rituximab monotherapy. To the best of our knowledge, a case of early onset PTLD following SOT after allo-HSCT has not been previously reported. This case highlights that PTLD can develop in patients with prolonged or compounded immunosuppression and emphasizes the importance of PTLD recognition and appropriate diagnosis and management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gastrointestinal-localized polymorphic post-transplant lymphoproliferative disorder following kidney transplantation after allogeneic hematopoietic stem cell transplantation: a rare case report

  • 期刊论文

  • 发表日期：

    2026年2月16日

查看全文
  • Yoshiki Morihisa,
  • Satoko Inoue,
  • Kohei Uyama,
  • Shotaro Ueno,
  • Takanari Minoshima,
  • Soichiro Nagao,
  • Yohei Yabuuchi,
  • Shigeo Hara,
  • Naoki Kanda

摘要

Post-transplant lymphoproliferative disorder (PTLD) is an uncommon but potentially life-threatening complication of solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). Therefore, early diagnosis and appropriate treatment are crucial. We report a case of a 37-year-old male who developed gastrointestinal-localized Epstein–Barr Virus (EBV)–associated polymorphic PTLD 5 months after kidney transplantation for diabetic nephropathy. The patient had undergone allogeneic HSCT (allo-HSCT) for acute myeloid leukemia 14 years prior and developed chronic graft-versus-host disease and secondary hypogammaglobulinemia. A reduction in immunosuppressive therapy was insufficient to control the PTLD, and the patient achieved complete remission with rituximab monotherapy. To the best of our knowledge, a case of early onset PTLD following SOT after allo-HSCT has not been previously reported. This case highlights that PTLD can develop in patients with prolonged or compounded immunosuppression and emphasizes the importance of PTLD recognition and appropriate diagnosis and management.